Cargando…
Correction Notice: A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280083/ https://www.ncbi.nlm.nih.gov/pubmed/34278232 http://dx.doi.org/10.1097/HS9.0000000000000619 |
| _version_ | 1783722577230823424 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8280083 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-82800832021-07-16 Correction Notice: A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure Hemasphere Correction Notice Lippincott Williams & Wilkins 2021-07-15 /pmc/articles/PMC8280083/ /pubmed/34278232 http://dx.doi.org/10.1097/HS9.0000000000000619 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Correction Notice Correction Notice: A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure |
| title | Correction Notice: A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure |
| title_full | Correction Notice: A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure |
| title_fullStr | Correction Notice: A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure |
| title_full_unstemmed | Correction Notice: A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure |
| title_short | Correction Notice: A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure |
| title_sort | correction notice: a study of safety and efficacy of nivolumab and bendamustine (nb) in patients with relapsed/refractory hodgkin lymphoma after nivolumab monotherapy failure |
| topic | Correction Notice |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280083/ https://www.ncbi.nlm.nih.gov/pubmed/34278232 http://dx.doi.org/10.1097/HS9.0000000000000619 |